The Bergen 4-Day Treatment Trial has successfully recruited the required number of participants. This marks a significant step towards evaluating the effectiveness of the treatment in relation to standard treatment and brings us closer to potentially implementing it.
The study aims to assess the non-inferiority, speed of recovery, and cost-effectiveness of the Bergen 4-Day Treatment (B4DT) for obsessive-compulsive disorder in comparison to the gold-standard cognitive-behavioral therapy with exposure and response prevention through a randomized controlled trial (RCT). CBT, while effective, typically spans 3-4 months with approximately half of patients remaining impaired post-treatment. B4DT, a concentrated treatment developed by Gerd Kvale and Bjarne Hansen from Bergen, entails four consecutive days of ERP at a clinic. Previous uncontrolled trials and one RCT have shown B4DT to achieve remission in about 70% of patients. However, direct comparison with gold-standard CBT is lacking, prompting the current study to address this gap.
The Bergen team from the Rück group and OCD-programmet has done an outstanding job by successfully recruiting 120 participants 👏👏
Rücklab - Psychiatry research at Karolinska Institutet 